Wolfe Center for Translational Medicine and Engineering will bring doctors, scientists and engineers together at Rambam to turn research into treatments faster, with work spanning AI, biochips, drug delivery, medical devices and regenerative medicine
The Technion and Rambam Health Care Campus have signed an agreement to establish a joint center aimed at accelerating the development of medical treatments and technologies by bringing physicians, scientists and engineers together under one roof.
The Andrea and Lawrence Wolfe Center for Translational Medicine and Engineering will be established in the Helmsley Health Discovery Tower at Rambam and will occupy two floors, the institutions said.
The center, funded through a donation from Andrea and Larry Wolfe, will include research laboratories focused on artificial intelligence in medicine, biochips, drug delivery and molecular therapies, medical devices, tissue engineering, regenerative medicine and health care systems.
The goal is to shorten the path between scientific and engineering research and clinical use, allowing problems identified at the patientโs bedside to become research projects and new discoveries to be translated more quickly into treatments.
Technion President Professor Uri Sivan and Rambam Director General Dr. Michal Mekel signed the agreement.
โThe joint agreement we are signing today is a natural continuation of the vision of the founders of the Ruth and Bruce Rappaport Faculty of Medicine, who understood the power of combining medicine, science, engineering and technology for the benefit of humanity,โ Sivan said.
โThe combination of a research hospital and a technological university provides the entire value chain, from the patientโs bedside to the research and development laboratories and back to the patientโs bedside.โ
Medical research at Technion (Photo: Courtesy of Technion)
Sivan also thanked Andrea and Larry Wolfe for supporting the project, describing them as longtime partners of both institutions.
โThis is a wonderful example of the power of philanthropy to drive major initiatives that would not otherwise get underway,โ he said. โAndrea and Larry have not only contributed generously but have embraced the vision at the heart of this collaboration โ the aspiration to solve major problems facing humanity by combining science, medicine and engineering.โ
Mekel said the center reflects the growing importance of cooperation between medicine and engineering. She cited Kurt Semm, regarded as a pioneer of modern laparoscopy, whose work combined medical expertise with engineering ingenuity.
โToday, as researchers and physicians, it is clear to us that medicine cannot exist and advance without research โ not only research in the life sciences, but also in engineering,โ Mekel said. โBreakthroughs emerge when different worlds meet, and in our case, when medicine meets engineering.โ
She also credited former Rambam director general Professor Rafi Beyar with advancing the vision for such a center nearly two decades ago.
Rambam team during specialized surgery (Photo: Rambam Health Care Campus)
Professor Noam Ziv, deputy senior executive vice president for engineering, life sciences and medicine at the Technion, said the center was being established amid a steady increase in joint projects involving Technion and Rambam researchers.
He pointed to a recent competition for a joint research grant on artificial intelligence in the โhospital of the future,โ won by a team that included researchers in architecture and data sciences alongside senior Rambam medical and administrative staff. The breadth of that team, he said, demonstrated the potential scope of collaboration between the institutions.
Prof. Lior Gepstein, director of Rambamโs Research Division and a faculty member at the Technionโs Rappaport Faculty of Medicine, said the center was intended to overcome traditional disciplinary boundaries.
โThe complex challenges of medicine do not stop at the boundaries of a single discipline,โ Gepstein said. โTo find new solutions, we must bring together medical teams with firsthand knowledge of patientsโ needs, scientists who investigate the mechanisms of life and engineers who know how to transform an idea into a practical solution.โ
Gepstein said the centerโs location inside Rambam was intended to facilitate a direct link between clinical needs and research.
โThe agreement we are signing today is not the finish line, but the starting point,โ he said. โThe centerโs success will be measured not only by the number of studies, papers or patents it produces, but by our ability to build a shared community, transform medical needs into practical solutions and bring those solutions to patients.โ
Senior officials from both the Technion and Rambam attended the signing ceremony, including administrators, researchers, medical leaders and representatives responsible for academic affairs, research, operations, finance and external relations.
Cutting-edge computational tools are helping Israeli doctors and scientists detect cancers earlier, understand them better and treat them more effectively
From his fourth-floor lab at the Technion-Israel Institute of Technology, Professor Ron Kimmel can see Haifa Bay, the green slopes of Mount Carmel and the distant hills of Galilee. But itโs the view of microscopic breast cancer cells on his computer screen that really excites him.
Kimmel is an expert in computer vision, machine learning, medical imaging and scientific computation. He believes artificial intelligence can dramatically improve the accuracy and efficiency of identifying cancer subtypes โ which, crucially, can help oncologists tailor treatments to individual patients.
โWeโre not trying to diagnose if a patient has cancer; these are already confirmed cases of invasive breast cancer,โ Kimmel said. โBut one of the challenges is deciding exactly which patient will benefit from which treatment. You donโt want to overtreat or undertreat.โ
Kimmel said that AI โ which can analyze large amounts of data from clinical trials โ is often more accurate than human observations, making it particularly useful in determining how to treat breast cancer.
AI is also the focus of Dr. Debbie Anaby, founder of the Breast Cancer Imaging Lab (BreaCIL) at Sheba Medical Center in Tel Aviv. Her aim is to minimize patient anxiety and slash the number of unnecessary biopsies by using AI-driven computational approaches for analyzing scans.
โMRI is the most sensitive imaging tool available to detect breast cancer โ especially for women at high risk like carriers of the BRCA mutation or those with a family history. But that high sensitivity also finds many lesions that appear suspicious, but ultimately turn out to be benign,โ Anaby said. โThe goal of my research is to develop AI-based tools to help radiologists distinguish more accurately between cancer and findings that are harmless.โ
Also at Sheba is Dr. Talia Golan, who leads the institutionโs Pancreatic Cancer Program and the Pancreatic Translational Research Lab. Among the most lethal of all cancers, pancreatic cancer is particularly difficult to treat. And like breast cancer, pancreatic cancer is more common among Ashkenazi Jews due to the increased presence of BRCA1 and BRCA2 mutations.
According to research, aboutย 1 in 40 Ashkenazi Jewsย carry a BRCA1 or BRCA2 mutation, which is 10 to 20 times higher than in the general population. While having a mutated or defective copy of the BRCA1 or BRCA2 gene can lead to pancreatic cancer,ย the risk is 2-6 times higherย than those who donโt have such mutations.
Golan said the last year or two has seen โleaps and bounds in the field of AI-guided researchโ when it comes to pancreatic cancer.
โScienceโs ability to integrate the full spectrum of research data โ including clinical data and all the other data points surrounding a patient โ and analyze it in an unfiltered way is limited,โ Golan said. โHowever, we can capture and integrate these data and use AI to predict which treatment trajectory is most likely to benefit each patient, based on analysis of very large cohorts.โ
Of course, despite all its promises, Golan cautions that AI can also be a double-edged sword.
Professor Ron Kimmel, who specializes in developing AI models to analyze tumors, displays a microscopic image of breast cancer cells at his lab at Haifaโs Technion-Israel Institute of Technology. (Photo credit: Larry Luxner)
โYou need to learn to use AI, but itโs like a monster,โ she said. โYouโve got to be careful because AI can predict things that are inaccurate. You need to have enough deep knowledge to identify inaccuracies, and you need to know what prompts youโre putting in to guide the AI.โ
What Kimmel, Anaby and Golan have in common isnโt just that all three are using AI to transform cancer research, treatment and diagnosis. All three have also been awarded grants from theย Israel Cancer Research Fundย (ICRF), an international nonprofit based in New York that invests in Israeli scientists leading global cancer research breakthroughs.
Alan Herman, ICRFโs executive director, said BRCA-mutant cancers โ particularly breast and pancreatic cancer โ remain among the most urgent challenges in oncology, and that AI is opening doors that traditional research methods simply couldnโt reach before.
โThese three projects reflect exactly what ICRF was built to support: bold science that will translate into real clinical impact for patients,โ said Herman, himself a cancer survivor. โWeโre proud to fund researchers who are using cutting-edge computational tools to find these cancers earlier, understand them more precisely and ultimately treat them more effectively.โ
Kimmel, who founded and leads the Technionโs Geometric Image Processing Lab, is receiving $180,000 in ICRF funding over a three-year period. That grant is going toward an AI model Kimmel is working on that is trained to analyze routine pathology samples to predict whether a breast cancer patient is likely to benefit from chemotherapy.
โTraditionally, doctors examine a few slices of a tumor using basic staining, and then perform more detailed tests on selected areas to understand its type and characteristics,โ Kimmel said. โOur AI-based method looks at all of these basic slides across the tumor, so it can capture features that may be missed in a few selected samples. We showed that this broader view can also help determine the best course of treatment.โ
Such a system requires only a digital scanner and internet access, making advanced analysis of biopsy samples possible in any clinic โ even in areas with limited medical resources. This technology โshould eventually lead to enhanced pathological methods and better prognostic tools for oncologists, and should ultimately improve the quality of life for patients worldwide,โ according to ICRF.
Anaby โ winner of an ICRF Career Development Award worth $135,000 over three years โ is working to combine advanced image processing, quantitative image analysis and AI to extract from breast MRIs information that clinicians donโt routinely use.
For example, Anaby said AI can detect extremely small lesions the human eye may miss; it can also help distinguish between cancerous and non-cancerous breast tumors.
โRather than treating breast MRI simply as a collection of images, we transform it into objective quantitative measurements that capture subtle imaging patterns within breast tissue,โ said Anaby, who works closely with Professor Miri Sklair-Levy, who is head of breast radiology at Sheba Medical Center. โWe then investigate whether these measurements reveal imaging signatures of cancer, and whether machine learning can use them to better distinguish malignant tumors from benign lesions and normal breast tissue.โ
Debbie Anaby, director of the Breast Cancer Imaging Lab at Israelโs Sheba Medical Center, is using an ICRF grant to research the use of AI in helping diagnose breast cancer earlier and reduce the number of unnecessary biopsies. (Courtesy of Sheba Medical Center)
At Sheba, women at high risk of breast cancer get MRI screenings once a year throughout their lives, from age 25 or 30 until their early 70s. Between 60% and 70% of those MRIs result in false positives, according to Anaby.
โThese women usually get more biopsies because doctors donโt want to take any chances,โ Anaby said. โItโs a very anxious time for these women.โ
Anaby said support from the Israel Cancer Research Fund allowed her team to take the first step. โThanks to ICRF, we were able to develop these models using data from Israeli patients,โ she said. โNext, we want to see whether these imaging patterns hold true for women of different backgrounds, so the knowledge we gain can help as many people as possible.โ
Anaby added that the ICRF grant โwill allow us to develop a new idea in-house, get some first results and then go on from there to a wider set of populations โ for Black, Hispanic and Asian women too, not just the Israeli population which includes a high percentage of Ashkenazi Jews with BRCA mutations,โ she said. โThat means a real mix of data.โ
Golan, who was born and raised in South Africa, has been at Sheba since 2004, where she treats pancreatic cancer, with a special interest in patients with inherited BRCA1 and BRCA2 mutations. Such patients, she said, generally respond well to platinum-based chemotherapy and PARP inhibitors, a type of targeted cancer drug.
Between 900 and 1,000 patients are diagnosed with pancreatic cancer annually in Israel; about 380 of them receive treatment at Golanโs clinic. Globally, around 5% of people with the disease have BRCA mutations, though in Israel the prevalence is higher.
โThere are new drugs that have recently received FDA approval, but itโs still a very aggressive cancer, and the five-year survival rate is quite low,โ she said, adding that besides genetic factors, pancreatic cancer is on the rise due to preventable causes such as obesity and smoking.
Golanโs five-year, $500,000 grant will fund the testing of new biological agents in pre-clinical settings using patient-derived models that mimic the patientsโ clinical journey.
โBy utilizing these preclinical model systems, we investigate mechanisms of resistance to biological treatment, and try to discover novel treatment combinations to improve the outcome for this unique subset of patients,โ she said. โAI will help us identify specific subtypes of patients who can benefit from precision treatment. Some can really benefit from intensive treatment, while for others, the best you can do for them is offer good palliative care.โ
For researchers embracing AI, the potential is huge, despite the risks. โItโs really a fascinating time,โ Golan said. โI myself am still learning this.โ
Stanford research places the Technion among the worldโs top universities outside the US for producing research masterโs graduates who go on to found billion dollar companies
LONDON, 13 August 2026: Behind every unicorn is an idea and behind some of the worldโs most successful technology companies is a Technion graduate.
New research led by Stanford University Professor Ilya Strebulaev, an expert in venture capital and innovation, has placed the Technion, Israel Institute of Technology, among the top 10 universities outside the United States for producing research masterโs graduates who have gone on to found deep tech unicorns, privately held companies valued at more than $1 billion.
The study identified 347 research masterโs graduates from 206 universities outside the US who went on to found 270 unicorn companies. The Technion produced seven of those unicorn founders, placing it among an elite group of universities worldwide.
It is the latest evidence of an entrepreneurial culture that has helped ideas born at the Technion grow into companies worth billions of dollars and technologies used by millions of people around the world.
For more than a century, the Technion has educated scientists, engineers, doctors, researchers and entrepreneurs who have gone on to shape Israelโs economy and make an impact far beyond its borders.
Research published by the Technion, based on data from the Samuel Neaman Institute, found that between 2015 and 2022, Technion graduates founded or managed 1,021 startup companies, approximately one quarter of all startups established in Israel during that period.
The Technion also educates approximately one third of the engineers graduating from Israeli universities and around half of Israelโs PhDs in science and engineering.
Perhaps the most spectacular recent example is Wiz. The cybersecurity company was cofounded and is led by Technion alumnus Assaf Rappaport, who completed his masterโs degree in computer science at the Technion.
Founded in 2020, Wiz experienced extraordinary growth, becoming one of the worldโs most valuable cybersecurity companies. In 2025, Google announced an agreement to acquire Wiz for approximately $32 billion, the largest acquisition in Googleโs history and the biggest exit in Israeli technology history. Before founding Wiz, Rappaport was also a cofounder of cybersecurity company Adallom, which was acquired by Microsoft in 2015.
Another Technion entrepreneurial success story is Armis, the cybersecurity company cofounded by Technion alumnus Nadir Izrael. Armis grew into a multibillion dollar global company protecting organisations and their connected assets. Izrael has spoken about how his time at the Technion helped prepare him for entrepreneurship, not only through his studies but through the relationships he formed there. It was at the Technion that he met the person who would eventually become his cofounder.
Other examples span the technology landscape. Silverfort, the identity security unicorn, was cofounded by Technion graduate Yaron Kassner. Technion alumna Merav Bahat cofounded and led cybersecurity company Dazz, which was acquired by Wiz in 2024 in a deal reported to be worth approximately $450 million.
These companies form part of a much larger ecosystem of businesses created and led by Technion graduates, spanning cybersecurity, software, medical technology, mobility, infrastructure, engineering and many other fields.
For Alan Aziz, CEO of Technion UK, the figures are significant not simply because of the valuations involved, but because of what they reveal about the people and ideas behind them.
Alan Aziz said: โPeople talk about unicorns because of the extraordinary numbers attached to them, a billion dollar valuation or a multibillion dollar acquisition. But for me, the most exciting part of this story comes long before any of that. It begins with a student, an idea and the belief that something can be done differently. The Technion gives brilliant people the knowledge and the environment to question what is possible and then the confidence to go out and build it. When you see companies such as Wiz and Armis growing from ideas into businesses operating on a global scale, you begin to understand the extraordinary impact a university can have. These companies create jobs and economic value, but more importantly they create technologies that solve real problems. The seven unicorn founders identified by this research are seven remarkable success stories. But they also represent something much bigger: generations of Technion graduates who have taken what they learned and used it to change the world.โ
The Stanford research is particularly significant because it focuses on deep tech unicorns, companies whose success is built around substantial scientific or engineering innovation. That connection between fundamental knowledge and real world application has been at the heart of the Technion since its creation.
The universityโs graduates have helped build Israelโs reputation as the Startup Nation, while creating companies and technologies whose influence extends far beyond Israel.
Across the Technion today, students and researchers are working on challenges spanning medicine, energy, water, cybersecurity, sustainable technology, transportation, computing and engineering.
Technion researchers have developed a membrane-free method to produce green hydrogen and the industrial chemical epoxide with 98% efficiency, potentially reducing production costs and enabling large-scale industrial use
Researchers at the Technion โ Israel Institute of Technology have developed a new method for producing green hydrogen that also generates a commercially valuable chemical known as epoxide. In a study published in the journal Nature Communications, the researchers demonstrated 98% efficiency in both processes without using a membrane to separate the electrodes. The research was led by Prof. Avner Rothschild and Dr. Guilin Ruan of the Technion, and a patent application for the technology has been filed in the United States.
Green hydrogen is considered one of the most important energy sources of the future. It is produced by splitting water using electricity from renewable sources and is expected to play a significant role in reducing greenhouse gas emissions in industries that are difficult to electrify directly. These include steel and fertiliser production, petroleum refining and the production of alternative transportation fuels.
Technion researchers added that green hydrogen could also support long-term storage of solar and wind energy. However, its industrial adoption remains limited because of its relatively high cost compared with hydrogen produced from natural gas or coal, processes responsible for approximately 2% of global carbon dioxide emissions.
“We approached this challenge by rethinking the water-splitting process. Our goal was to replace the oxygen normally produced alongside hydrogen with another product of much higher value โ an epoxide,” Rothschild explained. “Epoxides are essential building blocks in the production of polymers, coatings, adhesives, pharmaceuticals, and many other products.
“In the experiments presented in our paper, we demonstrate 98% efficiency both in hydrogen generation and in the parallel reaction that produces the epoxide. In other words, almost all the electrical charge drove the desired electrochemical reactions, with only 2% lost to competing processes. Moreover, the current density we achieved is compatible with large-scale industrial electrolysis.”
The Technion said the new process builds on a family of earlier technologies developed by Rothschild and his colleagues, all of which share a common principle: separating the electrochemical reaction that produces hydrogen from the one that produces oxygen. This separation forms the basis of membrane-free electrolysis, a technology that represents a major breakthrough in hydrogen production.
One of the earlier technologies in this family has been successfully implemented by H2Pro, a company developing hydrogen production technology. The latest development emerged from groundbreaking research supported by the European Research Council (ERC).
According to Ruan, one of the leading researchers on the team who conceived and developed the innovative process, “Our achievement goes beyond a single new electrode or an isolated chemical reaction. It represents a conceptual shift in which all the different components of the operating environment โ the electrodes, the mediator, the solvent environment and the operating configuration โ work together.
“By optimizing the entire system, we succeeded in producing both hydrogen and epoxide efficiently without the need for a membrane separating the electrodes.”
Dr. Guilin Ruan (Photo: Technion spokesperson’s office)
Rothschild heads the Technion’s Sustainability Frontier and is a faculty member in the Department of Materials Science and Engineering. He is also a member of the Stewart and Lynda Resnick Sustainability Center for Catalysis and the Nancy and Stephen Grand Technion Energy Program.
The research was funded by the European Research Council through the H2Bro project, following Rothschild’s receipt of the prestigious ERC Advanced Grant in 2023. The work is also associated with the interuniversity Waste to Value research initiative, funded by Israel’s Planning and Budgeting Committee of the Council for Higher Education. The researchers also acknowledged the Israel National Institute for Energy Storage (INIES).
The hospital-developed system analyses medical histories, laboratory results and imaging needs in real time, cutting admission delays and flagging hidden emergencies including a severe infection, suspected child abuse and a life-threatening potassium deficiency.
A new artificial intelligence system operating at Rambam Health Care Campus analyses the data of every patient in its emergency departments in real time, suggests possible diagnoses and treatments and identifies complex or unusual cases within seconds.
The system, named Shaked, has been in use at the Haifa hospital for the past six months. According to its developers, it has already shortened the time required to admit patients by one hour and reduced waiting time for specialist consultations in the adult and paediatric emergency departments by 25 minutes.
โThis is the first AI system involved at highly important decision-making points in the emergency department,โ said Prof. Shahar Shelly, director of Rambamโs Neurology Department and head of the artificial intelligence laboratory at the Technionโs medical faculty, who initiated and developed the system.
โWe believe waiting times will be shortened significantly in the near future. The results have already amazed us.โ
Artificial intelligence has assumed a growing role in health care in recent years. Hospitals and health funds are developing and adopting systems that analyze medical information, support clinical decisions and assist physicians in treating patients.
At the same time, the health system remains concerned about doctors independently using external AI products such as ChatGPT, Gemini or Claude, which may not operate within secure medical databases or under institutional oversight.
Shaked supports medical teams throughout the emergency-room process, from admission, diagnosis and treatment to the decision to hospitalize or discharge a patient.
The system consolidates each patientโs medical history, compares it with similar cases, receives and analyzes laboratory results and prioritizes imaging examinations such as CT scans in real time for all patients currently in the emergency department.
โThe system sends alerts to doctorsโ computers about specific patients whose condition could deteriorate within a short period, even when their clinical indicators appeared reasonable during triage,โ Shelly said.
It was gum inflammation, not a stroke
Shelly described a recent case in which the system identified severe gum inflammation in a patient whose symptoms initially appeared consistent with a stroke.
โA young woman arrived with neurological symptoms characteristic of a stroke, including paralysis on one side of her face that had developed very rapidly,โ he said.
โBecause of the suspected stroke, we were preparing to activate the stroke protocol, including an urgent CT scan. Although neither the patient nor the doctor made the connection, the system alerted us that two weeks earlier she had undergone a complex dental procedure that could become complicated, create a localised infection in the jaw and place pressure on the facial nerve.โ
(Photo: Elad Gershgoren)
An oral and maxillofacial specialist was summoned to the emergency department and determined that the woman was suffering from acute gum inflammation rather than a stroke.
Another particularly sensitive case occurred in Rambamโs pediatric emergency department after a 4-month-old girl arrived with a fractured thigh.
โThe parents suggested that their 3-year-old child may have fallen on her, but the system retrieved an emergency-room visit from a month earlier involving another injury,โ said Dr. Idit Pasternak, director of the pediatric emergency department at Rambamโs Ruth Rappaport Childrenโs Hospital.
โAnalyzing the case and combining the current fracture with the previous injury immediately raised suspicion of child abuse. Without the artificial intelligence, there would certainly have been a consultation with a specialist and a discussion involving the entire team, but in this case the Shaked system raised a red flag over an injury characteristic of abuse.โ
Because doctors believed the infantโs life could be at risk, they reported the case to the appropriate authorities without further delay.
A third case involved a 13-year-old boy who complained of muscle pain. According to Pasternak, the system analyzed his blood tests and alerted doctors to the possibility of severe hypokalemia combined with metabolic acidosis, a rare and life-threatening condition caused by an acute potassium deficiency.
โWithout immediate treatment, acute heart and respiratory failure can develop within a short time, leading to cardiac arrest and death,โ she said. โThe system saved valuable time. The doctors immediately confirmed the diagnosis and began lifesaving treatment.โ
โER lines will become a thing of the pastโ
Shelly said one of the principal causes of extended emergency-room stays is the wait for medical imaging, which can sometimes last several hours and create a risk of its own.
The system evaluates the patientโs symptoms, medical background, current clinical indicators and laboratory findings, compares them with existing medical literature and then recommends whether imaging is necessary and which cases should receive the highest priority.
Physicians review every recommendation and retain responsibility for the final decision.
โThe system identifies specific red flags for conditions such as internal bleeding, stroke, pulmonary embolism and others,โ Shelly said. โSuch a case will be placed at the top of the list and marked as urgent and requiring immediate action.โ
In the near future, the system is also expected to help prepare summaries of findings based on radiological interpretations.
Another tool incorporated into Shaked is a chat interface. Instead of opening dozens of previous patient visits to search for a specific piece of information, a physician can question the system about the patientโs file and medical history.
The tool operates using databases developed over decades within the hospital.
โOur AI does not have to go outside the system to mine information, but relies on the most up-to-date medical databases,โ Shelly said. โThis makes the teamsโ work more efficient in terms of both time and precision.โ
โSince we began operating the AI as a quiet adviser in the background, we have spared patients unnecessary CT scans and identified patients who need hospitalization more quickly,โ he added.
โThe system can refresh medical information in real time and changes with every result that arrives. That level of dynamism is the first of its kind.โ
The system was developed with the support of Rambamโs management and through collaboration involving Pasternak, Emergency Department Director Dr. Alexander Strizhevsky, nursing teams and the hospitalโs Digital and Information Technologies Division, headed by Hagar Trau, together with hospital developers Adi Ahituv and Keren Miron.
Dr. Michal Mekel, director of Rambam, said the hospital had placed innovation, and particularly the development of artificial intelligence, high on its list of priorities.
โWe are allocating extensive resources to provide our patients with the best and most advanced treatment in the world,โ she said. โWe are entering a new era in medicine.โ
โWe believe that within a short time, emergency-room lines will become a thing of the past, and we are moving toward a future of precise and rapid medicine that reduces cognitive bias.โ
In that future, she said, technology will serve as a lifesaving digital safety net, supporting doctors in their decision-making and freeing them to concentrate on what matters most: their human connection with the patient.
Haifa-based NurExone is preparing for human trials of an experimental therapy that uses engineered exosomes to restore function after spinal cord and optic nerve injuries.
“Our goal is to bring to market a therapy that could help people regain function after spinal cord injuries or restore vision following damage to the optic nerve,” says Dr. Lior Shaltiel, CEO of Haifa-based startup NurExone, which was founded on research conducted at the Technion and Tel Aviv University.
It is an ambitious goal. NurExone is attempting to tackle one of medicine’s most difficult challenges: repairing the central nervous system, where damaged nerves have long been considered largely incapable of regeneration. While doctors have learned to treat many of the complications associated with spinal cord and optic nerve injuries, they have had little success in reversing the damage itself. Patients with severe spinal cord injuries typically do not regain the ability to walk, while damage to the optic nerve often leads to permanent vision loss.
“The moment a spinal cord injury occurs – whether in a car accident or from a partial or complete severing of the cord, for example as the result of a gunshot wound – a secondary injury begins to spread,” explains Dr. Jacob Blumenthal, head of the BrainTech department at the Ehrlich Group, who was involved in the early research conducted at the Technion. “Cells in the affected area begin to die, effectively interrupting communication between the brain and the parts of the body it controls.”
Lior Shaltiel. (Photo: Michal Revivo)
Unlike the peripheral nervous system, where damaged nerves can regenerate, the central nervous system contains biological mechanisms that actively prevent damaged nerve fibers from regrowing.
“If I cut my hand and damage a peripheral nerve, it can regenerate,” explains Yoram Drucker, serial entrepreneur and chairman of NurExone. “But the central nervous system contains molecules that block the rehabilitation of damaged nerves.”
The company’s central question became straightforward: can those biological brakes be temporarily switched off?
Blocking the blocker
One of the key molecules responsible is a protein known as PTEN. Under normal circumstances, PTEN plays a critical role in protecting the body by preventing uncontrolled cell growth, helping suppress cancer. Following a nerve injury, however, the same protein also inhibits the regeneration of damaged nerve cells.
“We know there are inhibitors that prevent nerve growth,” says Drucker. “So the idea was simple: let’s inhibit the inhibitor. If we block the blocker, we allow nerves to regrow.”
The challenge is delivering such treatment directly into damaged nervous tissue without invasive surgery.
NurExone’s approach relies on exosomes, microscopic particles naturally secreted by cells to communicate with one another throughout the body.
“We use exosomes because they can do three things,” Drucker explains. “They naturally migrate toward injured tissue, they help reduce inflammation and promote healing, and they serve as delivery vehicles. We load them with the therapeutic molecule we need, they enter the damaged tissue, release their cargo, and that’s what produces the therapeutic effect.”
The therapeutic cargo consists of a genetically engineered small interfering RNA (siRNA) molecule that temporarily suppresses PTEN activity.
“By temporarily switching off PTEN, we remove the brake on nerve regeneration,” says Shaltiel. “Importantly, we do this only for a short period – roughly two to three weeks after the injury.”
From engineered tissue to exosomes
NurExone’s origins trace back to research led by Prof. Shulamit Levenberg of the Technion and Prof. Daniel Offen of Tel Aviv University, who later became co-founders of the company.
Initially, Levenberg’s team focused on implanting engineered tissue directly into damaged spinal cords.
“We suddenly saw the rats walking,” she recalls. “We expected to see some improvement, but instead they got up, stood on their own, bore weight and walked almost normally. It was an incredibly exciting moment.”
The next challenge was translating those results into a treatment suitable for people.
Performing spinal cord transplants through invasive surgery would be difficult to apply widely, prompting the researchers to ask whether they could use only the biologically active components released by the cells rather than transplanting the cells themselves.
The answer was exosomes.
“We administered only the exosomes through the nose, and again the rats recovered,” says Levenberg. “The animals began walking again. At that point we realized this could become a practical, non-invasive clinical therapy.”
Manufacturing billions of biological delivery vehicles
Producing exosomes at clinical scale presents another technological challenge.
“We grow the cells in bioreactors at 37 degrees Celsius,” explains Dr. Tali Kizhner, NurExone’s vice president of research and development. “The cells grow on tiny carriers inside the bioreactor and continuously secrete exosomes, allowing us to scale production.”
Founded in 2020, NurExone has raised approximately $20 million and is publicly traded on the Toronto Stock Exchange.
Part of the company’s strategy is to pursue regulatory pathways for orphan diseases, which can provide development incentives and potentially accelerate regulatory review.
“This is an extremely active field because there are still no effective treatments,” says Blumenthal. “The first company to successfully commercialize a therapy in this area could gain a significant competitive advantage. Strong patent protection also substantially increases the company’s value.”
The commercial opportunity could also be considerable. Drucker notes that roughly 50,000 new spinal cord injury patients are diagnosed annually across the Western world. The company is also developing treatments targeting optic nerve damage, including glaucoma, which affects an estimated 80 million people worldwide.
NurExone remains in the advanced preclinical stage and is preparing regulatory submissions to the U.S. Food and Drug Administration. The company expects to begin its first human clinical trial in Israel and the United States around 2027, subject to regulatory approval.
But Shaltiel believes the long-term vision extends beyond hospitals.
“Eventually, we’d like to move treatment from the emergency room to the ambulance,” he says. “Someone injured in a car accident could receive the therapy immediately from a paramedic to prevent the loss of nerve cells before they even arrive at the hospital.”
Levenberg shares a similar vision.
“I imagine this becoming available in every emergency department,” she says. “A patient arrives with a spinal cord injury, receives exosome treatment immediately, and we prevent further deterioration while giving the tissue the opportunity to regenerate. If that becomes possible, we could prevent many of the lifelong consequences that spinal cord injuries cause today.”
The vision remains several years away from being tested in humans. But if NurExone’s approach proves successful in clinical trials, it could challenge one of neuroscience’s longest-standing assumptions: that damage to the central nervous system is largely irreversible.
The eye can rebuild lost corneal stem cells by turning old cells back into stem cells, a discovery that could one day help restore vision.
Researchers have found that old, fully mature cells in the cornea can become stem cells again. The cells rebuilt the eyeโs stem cell supply even after every last stem cell had been destroyed.
Cells that had nearly stopped dividing pulled off the reversal and kept the tissue healthy for the rest of the animalโs life.
The cornea is the clear dome at the front of the eye, and losing its stem cells can rob a person of sight.
A repair system the body runs on its own raises the prospect that some blindness could one day be reversed without a transplant from a donor.
A cornea rebuilds itself
The cornea keeps itself clear thanks to a small, hidden workforce. Its own limbal stem cells sit in a narrow ring at the outer rim, called the limbus.
Their offspring travel inward to replace surface cells as they wear away.
A team led by Professor Ruby Shalom-Feuerstein, a stem cell biologist at the Technion-Israel Institute of Technology, set out to see what happens when that workforce is gone.
Working with mice, the researchers stripped away the entire ring of stem cells while leaving the surrounding tissue bed untouched. Through the clear cornea, they tracked the repair.
The cornea grew back. Tracing individual cells showed the new stem cells were not survivors that had escaped the scalpel but ordinary mature corneal cells that had reversed course.
Biologists call this dedifferentiation, a process in which a specialized cell reverts to a stem cell.
A remarkable transformation
The transformation was remarkably complete.
Within about 40 days, the reverted cells were almost indistinguishable from the corneaโs native stem cells, sharing more than 99 percent of their gene activity. Ordinary corneal cells share only 85 to 90 percent.
They also behaved like the real thing, supplying fresh surface cells and keeping the cornea clear for 6 months.
That result ran against a long-held assumption. Losing a tissueโs stem cells was thought to be irreversible, ending in scarring and disease, which is why serious repair has usually meant transplanting cells from elsewhere.
โWe were surprised to discover that the cornea can regenerate itself even after the destruction of all its stem cells,โ said Shalom-Feuerstein.
The oldest cells made a comeback
Cells reversing into stem cells was not new. Earlier work had caught committed cells in fast-renewing tissues doing it.
One influential study showed differentiated cells in the airway becoming stable, working stem cells after the resident ones were removed.
What stayed unclear was the reach of that ability. In those tissues the cells that reverted were young, made only days earlier, so no one knew whether genuinely old cells held the same capacity.
The cornea gave the team a way to test it. Because a corneal cellโs distance from the rim tracks its age, the researchers could pick out the eyeโs oldest cells.
These were mature cells sitting at the center that had spent about four months drifting inward and had all but retired from dividing. Even these old cells made a comeback.
When moved onto a stripped corneal rim, they switched their stem cell programs back on, rebuilt both the quiet reserve and the active working pool, and kept the cornea clear for nearly a year.
An immune cell trigger
Something had to tell those cells to change. The team traced the signal to macrophages, the immune cells that rush to any injury to clear debris and bacteria.
They flooded the stripped rim within a day or two, and cutting their numbers by about three-quarters left the stem cells largely unable to return.
The macrophages did more than clean up. As they gathered they released signaling molecules.
Two of them, a growth factor called IGF1 and an immune messenger called CCL2, did most of the work of nudging mature cells back toward a stem cell state.
Blocking the pair stalled the repair, and adding them back restored it.
The reversal has its limits
The reversal has firm limits. It only worked when the tissue bed that houses the stem cells came through the injury intact, and it stayed within the corneaโs own family of cells.
When cells from the conjunctiva, the membrane that covers the white of the eye, moved in to repopulate the corneaโs outer rim instead, they could not transform into corneal stem cells.
The surface clouded and filled with blood vessels โ the signature of blindness caused by stem cell loss.
The eye is not alone. In the skin, researchers have found that the stem cells responsible for hair color can shift in and out of a stem cell state as their surroundings change.
The finding suggests this kind of cellular flexibility is a normal part of tissue maintenance, not just an emergency response to injury.
A path toward restoring vision
Whether human corneas can do the same is not yet settled. The experiments ran almost entirely in mice, and the team could not directly test reversal in humanย corneal cells.
Working with donated human tissue, they found the same macrophage molecules helped cultured human stem cells keep their identity โ a sign the pathway may carry over.
The stakes are clearest for people who have lost the corneaโs stem cells to burns, infection, or disease. Their vision is already gone or fading.
The study shows that a mature cell, even a very old one, can revert to a fully functional stem cell and remain that way for life, provided the surrounding tissue and immune cells supply the right signals.
What remains unknown is how to trigger that process on demand and whether other organs possess the same hidden regenerative ability.
โThe next challenge is learning how to control it and how to use it for regenerative medicine,โ said Shalom-Feuerstein.
The study is published in the journalย Nature Communications.
Scientists at the Technion โ Israel Institute of Technology have developed an artificial intelligence tool that can predict a person’s risk of heart failure up to five years before symptoms appear.
The breakthrough, published in the journal npj Digital Medicine, could help doctors identify high-risk patients much earlier, allowing treatment to begin before serious damage is done.
Heart failure affects around 64 million people worldwide and is one of the leading causes of illness and hospital admissions, particularly in older adults.
The AI model analyses data from a routine 24-hour heart monitor (Holter ECG) and can detect tiny warning signs that are invisible to the human eye.
Professor Joachim Behar, who led the research at the Technion’s Faculty of Biomedical Engineering, said: “By identifying people at risk years before heart failure develops, we have an opportunity to intervene earlier, improve patients’ quality of life and potentially save lives.”
The model was developed using around 70,000 routine heart-monitoring tests from Leumit Health Services and was created in collaboration with researchers and clinicians from Rambam Health Care Campus, Shaare Zedek Medical Center, the Hebrew University of Jerusalem and other leading Israeli medical institutions.
The researchers hope the technology could eventually become part of routine healthcare, helping prevent heart failure before it starts.
Not long ago, artificial intelligence felt like something out of science fiction: It lived in futuristic movies and speculative headlines. Today, itโs woven quietly into our daily routines. AI helps us decide where to eat dinner, flags unusual health symptoms, and even drafts our emails.
But while AI has changed daily life, its impact within research universities may be even more profound. At the Technion, a revolution is unfolding. AI is not just another tool in the academic toolbox. It is transforming how research is done and how quickly discovery happens.
Technion President Prof. Uri Sivan describes AI as a kind of โsuperbrain,โ one we are all connected to. This superbrain can process staggering amounts of information, recognize patterns humans would miss, and solve problems at speeds that were unimaginable just a few years ago. For researchers, whose work depends on thinking, analysing, and discovering, AI has become an extension of their own minds.
A Tectonic Shift in Research
Across campus, researchers in fields as diverse as medicine, biology, physics, and mechanical engineering are integrating AI into their daily work. Tasks that once required months or even years of painstaking effort can now be completed in hours. Calculations once done by hand or simulations that took weeks to run are now executed almost instantly.
Prof. Mark Silberstein of the Andrew and Erna Viterbi Faculty of Electrical and Computing Engineering believes this transformation is only beginning. โWeโre seeing a tectonic shift in academic research,โ he said. โSoon, everyone will be using AI for one thing or another.
AI Revolution | Prof. Mark Silberstein
Within a year, he predicts, AI tools will be fully embedded in research across disciplines, and many researchers will build their own custom AI systems tailored to their work. The pace of change, he said, will only accelerate.
What does that look like in practice?
From the Test Tube to the Computer
For generations, scientific breakthroughs were born in laboratories filled with microscopes, test tubes, and experimental animals. Today, many of those experiments are beginning not in physical labs, but inside computers.
Ofer Strichman, professor of computational logic and computer science in the Faculty of Data and Decision Sciences, has watched this evolution firsthand. โEvery year we recruit new faculty,โ he explained, โand you can see how more and more scientists are computational experimentalists. Theyโre doing their research in the computer.โ
AI revolution | Prof. Ofer Strichman
Imagine developing a new drug. Traditionally, scientists tested one compound at a time, often beginning with animals. Itโs slow, expensive, and limited. Now imagine creating a detailed digital simulation of a human organ, a โvirtual organ,โ and testing not just one molecule, but millions of combinations. AI can analyze the results, identify the most promising candidates, and dramatically narrow down what needs to be tested in the lab. Instead of replacing laboratory work, computers supercharge it. Scientists can explore possibilities that would be impossible to test physically, then return to the lab with sharper focus and better odds of success.
Picture a physicist, for instance, trying to predict how 1,000 celestial bodies will move over the next 1,000 years. The math quickly becomes overwhelming. But with powerful computers, each celestial body can be modeled digitally, with the system calculating how every object influences the others. The simulation unfolds in virtual space, revealing patterns no human could calculate by hand.
โNowadays,โ Strichman said, โthe more computing power you have, the better your research results will be. Like having a bigger telescope, computers allow us to see farther.โ
Why Computing Power Matters
Behind every AI breakthrough lies a less glamorous but absolutely essential ingredient: computing power.
For more than 30 years, the Technion has operated a high-performance computing (HPC) facility: essentially a warehouse filled with powerful servers. These systems have long supported researchers running complex simulations, particularly in fields like physics and engineering.
3D render of High Performance Computing Building on Technion campus in Haifa
Traditionally, these computers relied on components called central processing units, or CPUs. You can think of a CPU as the brain of a computer. The Technion currently operates about 6,500 CPUs, and researchers typically wait just a couple of minutes to access one. But AI demands something different.
Modern AI systems rely heavily on graphics processing units, or GPUs. Originally designed to render video game graphics, GPUs are uniquely suited for the kind of massive, parallel calculations that AI requires. While a CPU handles tasks sequentially, a GPU can perform many calculations simultaneously, making it dramatically faster for AI workloads. The difference is enormous.
GPUs are not only expensive (each unit can cost around $250,000) but they also require specialized infrastructure. They consume large amounts of electricity and generate extraordinary heat, demanding sophisticated cooling systems and advanced networking to allow thousands of units to communicate seamlessly. The Technion currently has only 72 GPUs, which is far from sufficient. Researchers can wait four hours or more for access to one. In a world where speed determines competitiveness, those hours matter.
A Global Race
Around the globe, countries, universities, and technology companies are racing to dominate the AI frontier. Success depends not only on talent and ideas, but also on infrastructure. The institutions that build the most advanced computing systems gain a powerful edge in research, innovation, and economic development.
โThere is an arms race among countries and universities to achieve AI dominance. To be at the forefront of this field, we need to strengthen the capabilities we have at the Technion.โ
Prof. Mark Silberstein
At present, many Technion researchers must rely on industry partnerships to access advanced GPU systems because the University lacks sufficient in-house capacity. While collaboration with industry can be valuable, dependence creates limitations.
Complicating matters, Israelโs recent war with Hamas forced national and institutional priorities to shift and long-term infrastructure investments were necessarily delayed. Now, as the country looks toward rebuilding and strengthening its future, expanding AI infrastructure has become a strategic priority.
The Technion is taking a major step forward with the construction of the Martin and Grace Druan Rosman High-Performance Computer Data Centre. The facility is nearing completion and will provide a state-of-the-art home for next-generation computing.
Supported by Dr. Martin Rosman and Grace Druan Rosman through the American Technion Society, the new centre includes advanced electrical systems, cutting-edge cooling technologies, and high-speed communications networks โ all designed specifically to support powerful GPU-based systems. In simple terms: The building will be ready for the AI era.
Martin and Grace Rosman unveiling the supercomputing centre, 2023
High Stakes for Israel
For Israel, the implications extend far beyond campus. Israelโs reputation as the Startup Nation rests heavily on the strength of its scientific institutions. Many of the countryโs most successful technology companies trace their roots to Technion labs and classrooms. The engineers and entrepreneurs trained here help power Israelโs economy.
If the Technion falls behind in AI research infrastructure, the ripple effects could be significant. Conversely, if it leads, the impact could be transformative: accelerating medical breakthroughs, advancing clean energy solutions, strengthening national security, and fueling new industries.
โThe Technion is committed to educating the best engineers in the world, the most capable entrepreneurs,โ Silberstein said. โIsraelโs brainpower is our competitive advantage.โ
The AI revolution is here and itโs reshaping science, education, and industry. At the Technion, the question is not whether AI will transform research because that transformation is already underway. The question is how boldly and how quickly the University can build the infrastructure needed to lead.
Concrete shapes the world you live in, but its environmental toll is massive.ย Imagine, though, if the buildings around you could grow and breathe, helping to heal theย planet. This isnโt science fiction. Itโs the vision of CyanoCement. Developed by researchers from the Technion,ย Israelย Institute of Technology, this innovative biocement uses ancientย microbesย to redefine how we think about construction materials.
At the heart of CyanoCement are cyanobacteria, tiny photosynthetic organisms responsible for Earthโs first oxygen-rich atmosphere. By leveraging these extraordinary capabilities, the teamโPerla Armaly, Yuval Berger, Lubov Iliassafov, Keren Rosenblau, Yechezkel Kashi, and Shany Barathโcrafted a process where these microbes bind minerals and precipitate calcium carbonate, creating a solid without high emissions.
This biocement doesnโt just end its environmental work once installed. It continues to capture carbon dioxide from the air, actively working against the problem of atmospheric carbon. Unlike conventional methods, CyanoCement turns construction into part of the solution.
The material is designed for facades,ย interiorย panels, and decorative structures. By focusing on non-load-bearing elements, the team keeps the projectโs ambitions grounded, managing expectations with scientific precision.
Visible Green: A Living, Breathing Material
The green hue of CyanoCement isnโt painted on. Itโs the color of lifeโindicative of the cyanobacteria within. The design makes environmental benefits visible, offering a reassuring sign that sustainability is working, right before your eyes.
This innovative project emerged from the Disrupt Design Lab at Technion, in collaboration with the Applied Genomics Lab, marking a significant crossover between architecture and biology. Itโs a fusion rarely seen, yet wholly necessary for the future of sustainable design.
For a unique blend of nature and architecture, explore how theย Sofia Pavilion blends urban landscapeswith natural elements.
CyanoCement was honored with the Green Productย Award, celebrated for its meaningful impact and robust research. Itโs not just talkโthis material has substance and intention.
Learn how ancient materials are making a comeback withย Finnish designers crafting fashionย from shipwreck timber.
As we think about the future of architecture and sustainability, itโs time to reconsider the role of construction. CyanoCement poses a radical idea: buildings that are not only structures but contributors to the atmosphere. An idea thatโs difficult to ignore once it takes root in your mind.